{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:54:58Z","timestamp":1790456098838,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.dsx.2025.103335","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:58:06Z","timestamp":1764291486000},"page":"103335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Low dose pioglitazone (7.5\u00a0mg) provides efficacious glycemic control in Asian Indian patients with poorly controlled diabetes compared to 15\u00a0mg: A pilot randomized controlled parallel-group open-label trial over 12 months"],"prefix":"10.1016","volume":"19","author":[{"given":"Rohit","family":"Barnabas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Bhide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba Samad","family":"Memon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjiri","family":"Karlekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Phirke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayadhaarani","family":"Sekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyankatesh","family":"Shivane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Lila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6902-4639","authenticated-orcid":false,"given":"Tushar","family":"Bandgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2025.103335_bib1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1479164118825376","article-title":"Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes","volume":"16","author":"DeFronzo","year":"2019","journal-title":"Diabetes Vasc Dis Res"},{"key":"10.1016\/j.dsx.2025.103335_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.dsx.2025.103335_bib3","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00404-017-4480-z","article-title":"Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis","volume":"296","author":"Xu","year":"2017","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.dsx.2025.103335_bib4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.117.030458","article-title":"Pioglitazone prevents stroke in patients with a recent transient ischemic attack or ischemic stroke: a planned secondary analysis of the IRIS trial (Insulin resistance intervention after stroke)","volume":"137","author":"Yaghi","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.dsx.2025.103335_bib5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2025.103335_bib6","unstructured":"FDA pioglitazone drug approval package n.d. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/021073A_Actos.cfm (accessed April 15, 2025)."},{"key":"10.1016\/j.dsx.2025.103335_bib7","unstructured":"CDSCO piogliazone approval n.d. https:\/\/cdscoonline.gov.in\/CDSCO\/Drugs (accessed April 15, 2025)."},{"key":"10.1016\/j.dsx.2025.103335_bib8","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","article-title":"Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The pioglitazone 001 study group","volume":"23","author":"Aronoff","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2025.103335_bib9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1507\/endocrj.K05-067","article-title":"Safety and efficacy of low-dose pioglitazone (7.5 mg\/day) vs. standard-dose pioglitazone (15 mg\/day) in Japanese women with type 2 diabetes mellitus","volume":"53","author":"Majima","year":"2006","journal-title":"Endocr J"},{"key":"10.1016\/j.dsx.2025.103335_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijcard.2016.11.126","article-title":"The low dose (7.5mg\/day) pioglitazone is beneficial to the improvement in metabolic parameters without weight gain and an increase of risk for heart failure","volume":"227","author":"Adachi","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.dsx.2025.103335_bib11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.4103\/2230-8210.113766","article-title":"Efficacy and safety of pioglitazone in type 2 diabetes in the Indian patients: results of an observational study","volume":"17","author":"Balaji","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.dsx.2025.103335_bib12","first-page":"36","article-title":"Effect of low (7.5 mg\/day), standard (15 mg\/day) and high (30 mg\/day) dose pioglitazone therapy on glycemic control and weight gain in recently-diagnosed type 2 diabetes patients","volume":"63","author":"Panikar","year":"2015","journal-title":"J Assoc Phys India"},{"key":"10.1016\/j.dsx.2025.103335_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.17925\/EE.2022.18.1.63","article-title":"Indian phenotype characteristics among patients with type 2 diabetes mellitus: insights from a non-interventional nationwide registry in India","volume":"18","author":"Kalra","year":"2022","journal-title":"touchREV Endocrinol"},{"key":"10.1016\/j.dsx.2025.103335_bib14","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.diabres.2015.05.030","article-title":"Effect of low dose pioglitazone on glycemic control and insulin resistance in type 2 diabetes: a randomized, double blind, clinical trial","volume":"109","author":"Rajagopalan","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2025.103335_bib15","article-title":"Efficacy and safety of standard dose pioglitazone versus low-dose pioglitazone as an add on treatment in type 2 diabetes mellitus: a randomized controlled trial","volume":"13","author":"Rodrigues","year":"2023","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"10.1016\/j.dsx.2025.103335_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13098-017-0290-5","article-title":"Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis","volume":"9","author":"Filipova","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.dsx.2025.103335_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2024.102989","article-title":"Revised definition of obesity in Asian Indians living in India","volume":"19","author":"Misra","year":"2025","journal-title":"Diabetes Metabol Syndr: Clin Res Rev"},{"key":"10.1016\/j.dsx.2025.103335_bib18","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1038\/s41598-019-41854-2","article-title":"Efficacy and safety of pioglitazone monotherapy in type 2 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials","volume":"9","author":"Alam","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.dsx.2025.103335_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.dsx.2025.103335_bib20","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031508","article-title":"Pioglitazone on nonalcoholic steatohepatitis: a systematic review and meta-analysis of 15 RCTs","volume":"101","author":"Zhao","year":"2022","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.dsx.2025.103335_bib21","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1172\/JCI200523219","article-title":"Effects of the PPAR\u03b3 agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus","volume":"115","author":"Nagashima","year":"2005","journal-title":"J Clin Investig"},{"key":"10.1016\/j.dsx.2025.103335_bib22","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/dom.12099","article-title":"Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial","volume":"15","author":"Bray","year":"2013","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2025.103335_bib23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.metabol.2004.07.008","article-title":"Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial","volume":"54","author":"Smith","year":"2005","journal-title":"Metabolism"},{"key":"10.1016\/j.dsx.2025.103335_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.08.010","article-title":"Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials","volume":"68","author":"Zhu","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.dsx.2025.103335_bib25","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s13300-017-0273-4","article-title":"Pioglitazone and the risk of bladder cancer: a meta-analysis","volume":"8","author":"Filipova","year":"2017","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.dsx.2025.103335_bib26","first-page":"68","article-title":"Pioglitazone--where do we stand in India?","volume":"60","author":"Mohan","year":"2012","journal-title":"J Assoc Physicians India"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402125001523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402125001523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:49:01Z","timestamp":1773852541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402125001523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1871402125001523"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2025.103335","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low dose pioglitazone (7.5\u00a0mg) provides efficacious glycemic control in Asian Indian patients with poorly controlled diabetes compared to 15\u00a0mg: A pilot randomized controlled parallel-group open-label trial over 12 months","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2025.103335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103335"}}